Navigation Links
Calithera Biosciences Closes $40 Million in Series A Financing
Date:7/8/2010

pand its technology for targeting allosteric activating sites to other enzymes with therapeutic potential in cancer.

"Most drug discovery efforts are focused on identifying drugs that inhibit enzyme function," said Dr. Wells.  "But, interestingly, many cellular enzymes remain dormant until activated.  In the case of caspases, they can be activated on demand by mimicking the natural process with small molecules."

"I am excited about the novel chemical approach that Calithera is taking," said Chris Christoffersen, Ph.D., of Morgenthaler Ventures and Chairman of the Calithera Board.  "The technology to discover small molecules that target binding sites to activate, rather than inhibit, enzymes has the potential to be a powerful and broadly applicable approach to developing innovative therapies across many targets."  

Expert Leadership Team in Place

The management team of Calithera brings to the company both deep scientific expertise and extensive experience in drug development.  

Susan Molineaux, Ph.D., was most recently a founder and Chief Executive Officer of Proteolix, a company that developed proteasome inhibitors.  Proteolix was in late-stage clinical trials with carfilzomib in multiple myeloma when Onyx Pharmaceuticals acquired the company in 2009 for $851 million.  Prior to forming Proteolix, Dr. Molineaux held leadership positions at Rigel Pharmaceuticals and Praecis Pharmaceuticals.  Dr. Molineaux began her career as a scientist in the Immunology group at Merck.  

Mark Bennett, Ph.D., Senior Vice President of Research at Calithera, was Vice President of Research at Proteolix.  Pre
'/>"/>

SOURCE Calithera Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
7. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
11. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... December 23, 2014 The report ... its definition, classification, application and industry overview. This ... product cost structure. Production is separated by regions, ... raw materials, equipment, downstream client survey, marketing channels, ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Groton , Connecticut MORRISVILLE, N.C., May ... of APIs, intermediates and Drug Products to the pharmaceutical industry, ... announce the recent award by Pfizer Inc. as the 2008 ... Groton, Connecticut R&D center on May 1, 2009. The award ...
... Blinatumomab in NHL and ALL Highlighted at the ... Combination Data in Breast Cancer to Be Presented ... MeetingBETHESDA, Md., May 20 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ...
... WOODMERE, N.Y., May 19 In an eleventh-hour attempt ... QGLY ) has issued a press release claiming that ... a key staff member of a subsidiary of Quigley, and ... who have offered their own slate of Quigley,s Board of ...
Cached Biology Technology:Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 2Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 3Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 4Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Epitomics, Inc. announced today that it has signed a ... HealthCare). Epitomics will use its proprietary rabbit monoclonal antibody ... identification and validation. "Epitomics has had ... is a major expansion of our collaboration and confirms ...
... German . Medicines from plants ... that has nothing in common with what the researchers ... Ecology IME in Aachen, Germany, are doing. They use ... many other medications, cannot be chemically produced. Biologically ...
... persist in the often violently competitive realm of bacteria, ... University Bloomington biologists have learned that in one bacterium, ... cheaters and arrest their bids for dominance. ... suppress social cheaters," said Gregory Velicer, who with Ph.D. ...
Cached Biology News:Medicines from plants 2'Policing' stops cheaters from dominating groups of cooperative bacteria 2'Policing' stops cheaters from dominating groups of cooperative bacteria 3'Policing' stops cheaters from dominating groups of cooperative bacteria 4
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Proline-serine-threonine phosphatase-interacting protein 2...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Biology Products: